Skip to content

Inspection Record

Paxeuticals LLC — FDA 483 Findings

US FDAInspected 2026-04-20Published 2026-10-27 6 findingsDocumentation and recordsEquipment and facilityStability and storageQuality unit oversightProcess validation

Inspectors Yvins DezanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

2Equipment and facility

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent malfunctions, contamination, that would alter the safety, identity, strength, quality or purity of the drug product.

3Stability and storage

Drug products are not stored under appropriate conditions oftemperature, humidity, and light so that their identity, strength, quality, and purity are not affected.

4Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

5Process validation

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

6Equipment and facility

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Paxeuticals LLC company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.